Pharmacotherapy Considerations in Diabetes and Obesity: Setting Patients up for Success

References

• . Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults 1999–2010. JAMA. 2012;307:491–497
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: Center for Disease Control and Prevention, US Department of Health and Human Services; 2011. http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed May 17, 2013
   Google Scholar
• . Kenkre J, Tan T, Bloom S. Treating the obese diabetic. Expert Rev Clin Pharmacol. 2013;6(2):171–183
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Nauck M, Bergenstal RM, . American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Abrahamson MJ, Barzilay JI, . AACE comprehensive diabetes management. Endocr Prac. 2013;19(2):327–336
   PubMed Web of Science ®Google Scholar
• . Mechanick JI, Youdim A, Jones DB, . Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Endocr Prac. 2013;19(2):337–372
   PubMed Web of Science ®Google Scholar
• . Austin MM. Diabetes educators: partners in diabetes care and management. Endocr Prac. 2006;12( suppl 1):138–141
   PubMedGoogle Scholar
• . Chiu M, Austin PC, Manuel DG, Shah BR, Tu JV. Deriving ethnicspecific BMI cutoff points for assessing diabetes risk. Diabetes Care. 2011;34(8):1741–1748
   PubMed Web of Science ®Google Scholar
• . Cornell S, Dorsey VJ. Diabetes pharmacotherapy in 2012: considerations in medication selection. Postgrad Med. 2012;124(7):84–93
   PubMedGoogle Scholar
• . Meneghini LF. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab. 2011;96(11):3337–3349
   PubMed Web of Science ®Google Scholar
• . Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes. 2004;53(3):156–164
   Google Scholar
• . Bolen S, Feldman L, Vassy J, . Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386–399
   PubMed Web of Science ®Google Scholar
• . Krentz AJ. Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. Curr Med Res Opin. 2008;24(2):401–417
   PubMed Web of Science ®Google Scholar
• . Genovese S, DeBarardis G, Nicolucci A, . Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. Adv Ther. 2013;30(2):190–202
   PubMed Web of Science ®Google Scholar
• . Patil HR, Al Badarin FJ, Al Shami HA, . Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826–833
   PubMed Web of Science ®Google Scholar
• . Younk LM, Davis SN. Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2012;8(4):515–525
   PubMed Web of Science ®Google Scholar
• . Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34(4):789–794
   PubMed Web of Science ®Google Scholar
• . MacConnell L, Pencek R, Li Y, Maggs, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31–41
   PubMedGoogle Scholar
• . Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15(6):485–502
   PubMed Web of Science ®Google Scholar
• . Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab. 2013;15(1):3–14
   PubMed Web of Science ®Google Scholar
• . Wysham C, Lush C, Zhang B, Maier H, Wilhelm K. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(1):79–85
   PubMed Web of Science ®Google Scholar
• . Stenlof K, Cefalu WT, Kim KA, . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2012;15(4):372–382
   Web of Science ®Google Scholar
• . Foote C, Perkovic B, Neal V. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res. 2012;9(2):117–123
   PubMed Web of Science ®Google Scholar
• . Abdul-Ghani MA, Puckett C, Adams J, Cersosimo E, Triplitt C, DeFronzo RA. Initial triple combination therapy is superior to stepwise add-on conventional therapy in newly diagnosed T2DM. Poster and oral presentation at the 73rd annual American Diabetes Association Scientific Sessions; June 21–25, 2013; Chicago, IL
   Google Scholar
• . Chen JT, Yanovski JA. Obesity. In: Talbert RL, DiPiro JT, Matzke GR, Posey LM, Wells BG, Yee GC, eds. Pharmacotherapy: A Pathophysiologic Approach, 8th ed. New York: McGraw-Hill; 2011; http://www.accesspharmacy.com.millennium.midwestern.edu/content.aspx?aID=8013538. Accessed November 3, 2012
   Google Scholar
• . National Institute of Health, US Department of Health and Human Services. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 1998;98(4083):1–262
   Google Scholar
• . Food and Drug Administration. FDA drug safety communication: completed safety review of Xenical/Alli (orlistat) and severe liver injury. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety-InformationforPatientsandProviders/ucm213038.htm. Accessed April 24, 2013
   Google Scholar
• . Qsymia [package insert]. Mountain View, CA: Vivus; 2012
   Google Scholar
• . Allison D, Gadde K, Garvey WT, . Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2011;20:330–342
   PubMed Web of Science ®Google Scholar
• . Gadde K, Allison D, Ryan D, . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–1352
   PubMed Web of Science ®Google Scholar
• . Garvey T, Ryan D, Look M, . Two-year sustained weight loss and metabolic benefits with controlled release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308
   PubMed Web of Science ®Google Scholar
• . Belviq [package insert]. Zofingen, Switzerland: Arena Pharmaceuticals GmbH; 2012
   Google Scholar
• . O'Neil PM, Smith SR, Weissman NJ, . Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–1436. doi:10.1038/oby.2012.66
   PubMed Web of Science ®Google Scholar
• . Smith SR, Weissman NJ, Anderson CM, . Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) study group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256
   PubMed Web of Science ®Google Scholar
• . Fidler MC, Sanchez M, Raether B, . BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077
   PubMed Web of Science ®Google Scholar
• . Food and Drug Administration. FDA news release: FDA approves Belviq to treat some overweight or obese adults. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm. Accessed April 24, 2013
   Google Scholar
• . Standards of Medical Care in Diabetes—2013. Diabetes Care. 2013;36( Suppl 1):S27–S28
   PubMedGoogle Scholar
• . Vest AR, Heneghan HM, Schauer PR, . Surgical management of obesity and the relationship to cardiovascular disease. Circulation. 2013;127:945–959
   PubMed Web of Science ®Google Scholar
• . Schauer PR, Kashyap SR, Wolski K, . Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–1576
   PubMed Web of Science ®Google Scholar
• . Mingrone G, Panunzi S, De Gaetano A, . Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–1585
   PubMed Web of Science ®Google Scholar
• . Buchwald H, Estok R, Fahrbach K, . Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–256
   PubMed Web of Science ®Google Scholar
• . Hoy SM. Lorcaserin: a review of its use in chronic weight management. Drugs. 2013;73(5):463–473
   PubMed Web of Science ®Google Scholar